Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice

Thursday, May 8, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses ALG-055009, a selective thyroid hormone receptor beta agonist, which has shown promising results in inducing pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice. This suggests its potential for treating metabolic dysfunction-associated steatohepatitis. The findings highlight the drug's efficacy and its role in metabolic health.
Price reaction · baseline $4.87 (2025-05-08 close) · hit after-hours · 1 other ALGS headline(s) in the window, move may be shared
day 0 close
-8%
day 1 · peak
+16.6%
day 3
+14.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • ALG-055009 shows potential as a selective thyroid hormone receptor beta agonist.
  • Induces pro-metabolic and anti-fibrotic gene expression in the liver.
  • Demonstrated efficacy in diet-induced obese mice.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-055009?

ALG-055009 is a selective thyroid hormone receptor beta agonist.

What condition is ALG-055009 targeting?

It targets metabolic dysfunction-associated steatohepatitis.

What effects does ALG-055009 have in studies?

It induces pro-metabolic and anti-fibrotic gene expression in the liver.

In which model was ALG-055009 tested?

It was tested in diet-induced obese mice.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-055009 thyroid hormone receptor metabolic dysfunction steatohepatitis liver health
Last updated: May 8, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →